#1 Clinical Trials Search in Europe

Lonvoguran

Lonvoguran, a novel drug developed by Intellia Therapeutics, is currently undergoing clinical trials for the treatment of Hereditary Angioedema (HAE). This article explores the ongoing research, potential benefits, and important information for patients regarding Lonvoguran and its use in HAE management.

Table of Contents

What is LONVOGURAN?

LONVOGURAN is an innovative medication being developed to treat Hereditary Angioedema (HAE), a rare genetic disorder[1]. It is part of a drug called NTLA-2002, which contains two active ingredients: LONVOGURAN and ZICLUMERAN. LONVOGURAN is also known as a single guide RNA targeting the human KLKB1 gene or hu-G012267[2].

How Does LONVOGURAN Work?

LONVOGURAN works through an advanced medical technology called gene editing. It specifically targets the KLKB1 gene, which is involved in the production of a protein that plays a role in HAE attacks. By modifying this gene, LONVOGURAN aims to reduce the frequency and severity of HAE attacks[1].

LONVOGURAN works together with ZICLUMERAN, which is a messenger RNA encoding Cas9. These two components are delivered to cells using lipid nanoparticles, tiny particles that help the medication enter the body’s cells[2].

What is Hereditary Angioedema?

Hereditary Angioedema (HAE) is a rare genetic condition that causes recurrent episodes of severe swelling. These swelling attacks can affect various parts of the body, including the hands, feet, face, airway, and intestinal wall. HAE attacks can be painful, disfiguring, and even life-threatening if they affect the airway[1].

Clinical Trials and Research

LONVOGURAN is currently being studied in clinical trials to evaluate its safety and effectiveness in treating HAE. These trials include:

  1. A long-term safety study for patients who have previously received NTLA-2002[1].
  2. A Phase 1/2 study to evaluate the safety, tolerability, and effectiveness of NTLA-2002 in adults with HAE[2].

These studies aim to determine the optimal dose of the medication and assess its impact on reducing HAE attacks[2].

Potential Benefits

The main goals of LONVOGURAN treatment are to:

  • Reduce the frequency of HAE attacks[2]
  • Decrease the severity of HAE attacks[2]
  • Improve quality of life for people with HAE[2]
  • Potentially provide long-term control of HAE symptoms[1]

Safety and Side Effects

As LONVOGURAN is still in clinical trials, its full safety profile is not yet known. The ongoing studies are closely monitoring for any side effects or adverse reactions. Some potential areas of concern being evaluated include:

  • Liver function changes[2]
  • Changes in blood clotting[2]
  • Infusion-related reactions[2]

It’s important to note that all medications can have side effects, and the benefits and risks will be carefully evaluated as research continues.

Administration

LONVOGURAN, as part of NTLA-2002, is administered through intravenous infusion. This means it is given directly into a vein. The exact dosing schedule is still being determined through clinical trials[2].

Conclusion

LONVOGURAN represents a promising new approach to treating Hereditary Angioedema. By targeting the genetic root of the condition, it may offer long-term benefits for people living with HAE. However, as the medication is still in clinical trials, more research is needed to fully understand its effectiveness and safety profile. Patients with HAE should consult with their healthcare providers about current treatment options and the potential for new therapies like LONVOGURAN in the future.

Aspect Details
Drug Name Lonvoguran (part of NTLA-2002)
Developer Intellia Therapeutics Inc
Target Condition Hereditary Angioedema (HAE)
Clinical Trial Phase Phase 1/2
Administration Method Intravenous infusion
Mechanism of Action Targets KLKB1 gene using CRISPR/Cas9 technology
Primary Objectives Evaluate safety, identify optimal dosage, assess effect on HAE attacks
Key Endpoints Number of HAE attacks, changes in plasma kallikrein levels, safety profile
Eligibility Adults with confirmed HAE Type I or II, meeting specific health criteria

FAQ

  • What is Lonvoguran and how does it work? Lonvoguran is a single guide RNA targeting the human KLKB1 gene. It works together with another substance called Ziclumeran (mRNA encoding Cas9) to potentially modify the genetic cause of Hereditary Angioedema, aiming to reduce the frequency and severity of HAE attacks.
  • What is the current stage of clinical trials for Lonvoguran? Lonvoguran is currently being studied in Phase 1/2 clinical trials. These trials are evaluating its safety, tolerability, pharmacokinetics, and pharmacodynamics in adults with Hereditary Angioedema.
  • How is Lonvoguran administered? Lonvoguran is administered as an intravenous infusion. It is part of a treatment called NTLA-2002, which consists of lipid nanoparticles containing Lonvoguran and Ziclumeran.
  • What are the main objectives of the current clinical trials? The main objectives include evaluating the safety of NTLA-2002, identifying appropriate doses, and assessing its effect on reducing HAE attacks. The trials also aim to measure changes in plasma kallikrein levels and quality of life improvements for patients.
  • Who is eligible to participate in these clinical trials? Eligible participants are adults (18 years or older) with a confirmed diagnosis of HAE Type I or II. They must have experienced a certain number of HAE attacks in recent months and meet specific health criteria. Detailed eligibility requirements are determined by the study investigators.

Ongoing Clinical Trials on Lonvoguran

  • Long-Term Safety Study of NTLA-2002 for Patients with Hereditary Angioedema, Using Messenger RNA Encoding Cas9 and HU-G012267

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany The Netherlands

  • Study on NTLA-2002 for Treating Hereditary Angioedema in Patients: Evaluating the Effects of Ziclumeran and Lonvoguran

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany The Netherlands

  • Study on NTLA-2002 for Adults with Hereditary Angioedema Using Ziclumeran and Lonvoguran

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    France Germany The Netherlands

Glossary

  • Hereditary Angioedema (HAE): A rare genetic disorder characterized by recurrent episodes of severe swelling in various parts of the body, including the limbs, face, intestinal tract, and airways.
  • KLKB1 gene: A gene that provides instructions for making a protein called plasma kallikrein, which is involved in several body processes, including inflammation and blood pressure regulation. In HAE, this gene is targeted by Lonvoguran.
  • Lipid nanoparticles: Tiny particles made of fat molecules that can carry and deliver drugs or genetic material into cells. In this case, they are used to deliver Lonvoguran and Ziclumeran.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and the relationship between drug concentration and effect.
  • Adverse Events (AEs): Any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medical treatment or procedure.
  • CRISPR/Cas9: A gene-editing technology that can be used to modify DNA sequences. In this context, it's being used as part of the treatment approach for HAE.

References

  1. http://clinicaltrials.eu/trial/long-term-safety-study-of-ntla-2002-for-patients-with-hereditary-angioedema-using-messenger-rna-encoding-cas9-and-hu-g012267/
  2. http://clinicaltrials.eu/trial/study-on-ntla-2002-for-adults-with-hereditary-angioedema-using-ziclumeran-and-lonvoguran/